Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Price:
44.71 USD
-2.47%
Market Closed
Updated:
Jun 9, 2024
Crinetics Pharmaceuticals Inc
Net Income (Common)
|
Crinetics Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
|
Net Income (Common)
-$235.5m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Crinetics Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-235.5m
USD
-235.5m
USD
Based on the financial report for Mar 31, 2024, Crinetics Pharmaceuticals Inc's Net Income (Common) amounts to -235.5m USD.
What is Crinetics Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-50%
-50%
Over the last year, the Net Income (Common) growth was -34%. The average annual Net Income (Common) growth rates for Crinetics Pharmaceuticals Inc have been -44% over the past three years , -50% over the past five years .
You don't have any saved screeners yet
